What is the latest research on scleroderma? Find out in this collection of recent MEDLINE abstracts compiled by the editors at Medscape Nurses. Acute and chronic renal diseases remain common ...

DEAR MAYO CLINIC: I'm a 50-year-old woman recently diagnosed with scleroderma. What causes it, and can anything stop its progression? What medications are available, and at what point should I begin ...

The prognosis for patients diagnosed with scleroderma - an autoimmune disease characterized by fibrosis of the skin - is not typically a rosy one. With limited treatment options available, those ...

Researchers found a unique immune cell plays a key role in the chronic inflammation and scarring in the lungs and skin of people with scleroderma, or systemic sclerosis. After injecting mice with ...

The "Systemic Scleroderma Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Regions; Segment Forecast, 2021-2028" report has been added to ResearchAndMarkets.com’s ...

Please provide your email address to receive an email when new articles are posted on . The last 3 years of drug development in scleroderma have come to represent everything that ails the current ...

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

LA JOLLA, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc. (MNOV), a biopharmaceutical company traded on the NASDAQ Global Market and the Standard Market of the Tokyo Stock Exchange (Code ...

Epigenetic drugs that have shown promise in cancer trials significantly reduce scarring in the cells of patients with scleroderma, a new study shows. Results reveal that drugs that inhibit BRD4, known ...

An unusual autoimmune disease that causes skin and lung damage can be treated effectively by stem cell transplant, a new study in the New England Journal of Medicine has found. The approach could ...

MediciNova Inc (NASDAQ:MNOV) Wednesday announced it has received a Decision to Grant from the European Patent Office for a new patent which covers MN-001 (tipelukast) for the treatment of scleroderma ...

For the 300,000 Americans living with the immune disease scleroderma, better treatments can't come soon enough. The rare and sometimes fatal illness stiffens and scars tissue in organs like the lungs, ...